Exelixis (EXEL) to Release Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is scheduled to be releasing its earnings data after the market closes on Tuesday, April 30th. Analysts expect Exelixis to post earnings of $0.28 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The business had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $23.70 on Friday. The company has a 50 day simple moving average of $22.80 and a two-hundred day simple moving average of $22.19. Exelixis has a fifty-two week low of $18.08 and a fifty-two week high of $24.34. The company has a market capitalization of $6.99 billion, a price-to-earnings ratio of 37.03, a P/E/G ratio of 0.61 and a beta of 0.54.

Analysts Set New Price Targets

A number of brokerages have issued reports on EXEL. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. Stifel Nicolaus upped their price target on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $27.00 target price on shares of Exelixis in a report on Wednesday, April 10th. Finally, Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target for the company. in a research note on Thursday, April 11th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.29.

Insider Transactions at Exelixis

In related news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now owns 35,703 shares in the company, valued at approximately $857,229.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director David Edward Johnson acquired 190,000 shares of Exelixis stock in a transaction dated Wednesday, February 21st. The shares were acquired at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Alan M. Garber sold 19,205 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares in the company, valued at $857,229.03. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.